Geron Corp (GERN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Geron Corp (GERN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012257
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc. IMbark is a Phase II, randomized, single-blind and multi-center study for patients with high risk myelofibrosis (MF) whose disease is relapsed after or refractory to JAK inhibitor treatment; and IMerge is a Phase 2/3, multi-center study of imetelstat in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS). Geron also has collaboration and royalty agreements with companies in oncology, diagnostics, biologics and research tools production domains. Geron is headquartered in Menlo Park, California, the US.

Geron Corp (GERN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Geron Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Geron Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Geron Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Geron Corp, Medical Devices Deals, 2011 to YTD 2017 9
Geron Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Geron Corp, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 11
Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 12
GE Healthcare Expands Licensing Agreement With Geron For Stem Cell Assays 14
Equity Offering 15
Geron Plans to Raise up to USD50 Million in Public Offering of Shares 15
Geron Completes Public Offering Of Shares For US$103.5 Million 16
Geron Announces Public Offering Of Shares For Up To US$50 Million 18
Asset Transactions 19
BioTime Completes Acquisition Of Stem Cell Assets From Geron 19
Geron Corp – Key Competitors 21
Geron Corp – Key Employees 22
Geron Corp – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Nov 01, 2017: Geron Reports Third Quarter 2017 Financial Results 24
Aug 09, 2017: Geron Reports Second Quarter 2017 Financial Results 25
May 09, 2017: Geron Reports First Quarter 2017 Financial Results and Recent Events 26
Mar 01, 2017: Geron Reports Fourth Quarter and Annual 2016 Financial Results 28
Nov 03, 2016: Geron Reports Third Quarter 2016 Financial Results and Recent Events 30
Aug 03, 2016: Geron Corporation Reports Second Quarter 2016 Financial Results and Recent Events 32
May 05, 2016: Geron Reports First Quarter 2016 Financial Results and Recent Events 33
Feb 25, 2016: Geron Reports Fourth Quarter and Annual 2015 Financial Results 35
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Geron Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Geron Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Geron Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Geron Corp, Deals By Therapy Area, 2011 to YTD 2017 8
Geron Corp, Medical Devices Deals, 2011 to YTD 2017 9
Geron Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 11
Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 12
GE Healthcare Expands Licensing Agreement With Geron For Stem Cell Assays 14
Geron Plans to Raise up to USD50 Million in Public Offering of Shares 15
Geron Completes Public Offering Of Shares For US$103.5 Million 16
Geron Announces Public Offering Of Shares For Up To US$50 Million 18
BioTime Completes Acquisition Of Stem Cell Assets From Geron 19
Geron Corp, Key Competitors 21
Geron Corp, Key Employees 22

★海外企業調査レポート[Geron Corp (GERN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Denali Therapeutics Inc (DNLI):製薬・医療:M&Aディール及び事業提携情報
    Summary Denali Therapeutics Inc (Denali Therapeutics) is a clinical-stage biopharmaceutical company that focuses on the development of therapeutics for the treatment of neurodegenerative diseases. The company’s proprietary drug delivery platform technologies include antibody transport vehicle and en …
  • Mega International Commercial Bank Co Ltd:企業の戦略・SWOT・財務情報
    Mega International Commercial Bank Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Mega International Commercial Bank Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Otto Bock HealthCare GmbH:企業の戦略的SWOT分析
    Otto Bock HealthCare GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • ENERQOS SpA:電力:M&Aディール及び事業提携情報
    Summary Enerqos SpA (Enerqos), a subsidiary of Climate Change Capital Private Equity LP, is an energy service company that offer solutions to improve energy efficiency. The company operates in the planning, management, financing and monitoring of projects in the renewable energy sector. It implement …
  • Sino Hotels (Holdings) Limited:企業の戦略・SWOT・財務分析
    Sino Hotels (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary Sino Hotels (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Dabur India Ltd (DABUR):企業の財務・戦略的SWOT分析
    Dabur India Ltd (DABUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Genera Biosystems Ltd (GBI):製品パイプライン分析
    Summary Genera Biosystems Ltd (GBL) is a developer and commercializer of multiplexed molecular diagnostic testing products. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pat …
  • Protagonist Therapeutics Inc (PTGX):企業の財務・戦略的SWOT分析
    Protagonist Therapeutics Inc (PTGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Core Laboratories NV (CLB):企業の財務・戦略的SWOT分析
    Core Laboratories NV (CLB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Enel SpA (ENEL)-石油・ガス分野:企業M&A・提携分析
    Summary Enel S.p.A. (Enel) is an energy group that produces, distributes and trades electricity and natural gas. The group generates electricity using diverse sources of energy such as nuclear, renewables, oil and gas turbine, coal and gas combined cycle. It also focuses on digitizing electricity gr …
  • Lexmark International Inc:医療機器:M&Aディール及び事業提携情報
    Summary Lexmark International Inc (Lexmark) a subsidiary of Ninestar Corp., provider of imaging and printing solutions. It manufactures, develops and supplies printing and imaging solutions, managed print services, device management, document workflow, business process and content management solutio …
  • Shunfeng International Clean Energy Ltd (1165):電力:M&Aディール及び事業提携情報
    Summary Shunfeng International Clean Energy Ltd (Shunfeng International), formerly Shunfeng Photovoltaic International Ltd is a renewable energy company that manufactures and markets solar photovoltaic products. The company’s products include monocrystalline silicon solar cells, polycrystalline sili …
  • Allinky Biopharma SL:医療機器:M&Aディール及び事業提携情報
    Summary Allinky Biopharma SL (Allinky) is a developer of small molecules for the treatment of cancer and inflammatory diseases. The company offers research and development of basic and clinical sciences and discovery of novel therapies. Its therapeutic agents comprise active site drugs, target prote …
  • SAES Getters SpA (SG):企業の財務・戦略的SWOT分析
    SAES Getters SpA (SG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • FXI, Inc.:企業の戦略的SWOT分析
    FXI, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Yanzhou Coal Mining Co Ltd:戦略・SWOT・企業財務分析
    Yanzhou Coal Mining Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Yanzhou Coal Mining Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • RentPath, LLC:企業の戦略・SWOT・財務分析
    RentPath, LLC - Strategy, SWOT and Corporate Finance Report Summary RentPath, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Savara Inc (SVRA):医療機器:M&Aディール及び事業提携情報
    Summary Savara Inc (Savara) formerly Mast Therapeutics Inc is a clinical stage biopharmaceutical company, which develops therapies for the treatment of rare respiratory diseases, including cystic fibrosis (CF), and pulmonary alveolar proteinosis (PAP). The company’s lead product candidates include M …
  • Innophos Holdings Inc (IPHS):企業の財務・戦略的SWOT分析
    Innophos Holdings Inc (IPHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Vertex Pharmaceuticals Incorporated:企業の戦略・SWOT・財務分析
    Vertex Pharmaceuticals Incorporated - Strategy, SWOT and Corporate Finance Report Summary Vertex Pharmaceuticals Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆